Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on improving the lives of those affected by kidney disease, will have its Chief Financial Officer, David Spellman, participate in a virtual fireside chat at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on improving the lives of those affected by kidney disease, will have its Chief Financial Officer, David Spellman, participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. An audio replay of the conversation will be available on the Investors section of Akebia's website for 90 days post-conference. Founded in 2007 and headquartered in Cambridge, MA, Akebia is dedicated to developing therapeutics for kidney patients.
Details
News Market Reaction – AKBA
The recorded move for AKBA in the trading session of this news was +2.71%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that David Spellman, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Conference, which will take place virtually January 10-13, 2022.
An audio replay of the fireside chat will be available through the Investors section of Akebia's website at https://ir.akebia.com for approximately 90 days following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
Mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-hc-wainwright-bioconnect-conference-301456833.html
SOURCE Akebia Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.